The carcinogenesis of METTL3 and YTHDF2 in prostate cancer and bladder cancer mainly contributes to the inhibition of antitumour genes and the promotion of oncogenes, resulting in tumour development. This evidence concerns the gene METTL3 and prostate carcinoma.